This is a recorded version of the AACC webinar, The Role of Biomarkers of Inflammation in Cardiovascular Disease, which was originally held March 13, 2012. Markers of inflammation can be successfully used to determine the risk of cardiovascular disease (CVD). However, there are some limitations to their use. Dr. Paul Ridker discusses the uses and limitations of inflammatory biomarkers such as hsCRP in the detection of cardiovascular risk, as well as how to compare and contrast information gained using the Framingham Risk Score to data from the Reynolds Risk Score. He also addresses how hsCRP and Lp-PLA2 compare as markers of inflammation.